Behandeling Amerika

What is the purpose of this research study?
 
Childeren with high-risk neuroblastoma often respond to standard treatment at first,but there is a high risk that the cancer will come back.
This study is being done to try and improve the likelihood that cancer will not come back in childeren with high-risk neuroblastoma.
 
Prior to participation in this study you received chemotherapy,surgery,radiation therapy,and stem cell treatment.
You responded to treatments.
The purpose of this companion study is to evaluate an experimental treatment aimed at maintaining or improving your response to previous treatments.
 
 
01. Ch 14.18,a monoclonal antibody
 
this study involves the use of an investigational biologic therapy,ch14.18,a monoclonal antibody.
Monoclonal antibodies are proteins made in the lab,designed to attach to neuroblastoma cells and other cancer cells that have GD-2 on their cells.
When ch 14.18 attaches to the neuroblastoma cells,the body's immune system is stimulated to attack and kill the neuroblastoma cells.
Ch14.18 represents a new kind of cancer therapy that,unlike chemotherapy and radiation,targets the destruction of cancer cells without destroying nearby healthy cells.
 
 
 
 
02. GM-CSF:
 
is a substance that is similar to a substance made by the body in all induviduals.
Under normal circumstances, the body makes a small amounts of GM-CSF that helps to produce normal infections fighting white blood cells.
It is now possible to make GM-CSF outside of the body and give humans much higher doses than their own body makes.
There is some evidence that,in the lab and in animals,GM-CSF increases the anti-cancer effect of monoclonal antibodies like ch 14.18.
 
 
03. IL 2 (Aldesleukin)
 
is a substance that is similar to the substance made by the body of all individuals.
Under normal circumstances,the body makes small amounts of IL-2 that helps white blood cells fight infections.
It is now possible to make IL-2 outside the body and give humans much higher doses than their own body makes.
There is some evidence that,in the lab and in animals,IL-2 increases the anti-cancer effect of monoclonal antibodies like ch 14.18.
We wish wish to study whether IL-2 can help improve the efficacy of ch 14.18 in humans.
 
 
Once you are registered on this study,you wil receive the experimental treatment
 
ch 14.18 + IL-2 + GM-CSF + Accutane.
 
 
it is important to keep in mind that ch 14.18 is an experimental drug and it is impossible to predict wheter or not you will benefit from its use.
However,early results from this study show that the experimental treatments works better than standard treatment to help get rid of any remaining
neuroblastoma cells for as long as possible!